Innovative Vaccine Platform Jurata Thin Film is at the forefront of biotechnology with its focus on revolutionizing vaccines and biologics by eliminating cold storage requirements and enabling rapid manufacturing, presenting opportunities to supply materials, equipment, or technology that support stable vaccine formulations.

Strategic Collaborations The company’s active partnerships with global health organizations like CEPI and Gates Foundation signals strong interest from funders and collaborators in advanced vaccine delivery systems, creating avenues for joint ventures, funding opportunities, or licensing arrangements.

Growing Funding Momentum After securing $4.87 million in seed funding and a significant $1 million grant, Jurata is demonstrating robust financial backing and growth potential, indicating a market readiness for innovative vaccine technologies that can be supported through supply chain solutions or manufacturing support.

Room-Temperature Storage Focus Jurata’s development of wafer-like, room-temperature stable mRNA films offers promising sales opportunities in logistics, cold chain reduction, and distribution services for global markets aiming to improve vaccine access and delivery convenience.

Emerging Market Demand The company's work on needle-free and oral vaccine delivery methods addresses increasing market demand for convenient, needleless immunization options, opening opportunities for companies involved in device integration, compliance, and patient engagement solutions.